A simple method to induce hypoxia-induced vascular endothelial growth factor-A (VEGF-A) expression in T24 human bladder cancer cells

Autor(es)

Santos Cesario, Jonas Magno ; Oliveira Brito, Rodrigo Barbosa ; Malta, Camila Soares ; Silva, Chrisna Souza ; Teles Matos, Yves Silva ; Macedo Kunz, Tania Cristina ; Urbano, Jessica Julioti ; Franco Oliveira, Luis Vicente ; Dalboni, Maria Aparecida ; Delle, Humberto

• Tipo de documento: Artigo Científico
• Fonte: IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL; v. 53, n. 3, p. 272-276, MAR 2017.
• Citações Web of Science: 0

Resumo

Angiogenesis is an essential process for the establishment, development, and dissemination of several malignant tumors including bladder cancer. The hypoxic condition promotes the stabilization of hypoxia-inducible factor 1 alpha (HIF-1 alpha), which translocates to the nucleus to mediate angiogenic factors including the vascular endothelial growth factor A (VEGF-A). AnaeroGen system was developed for microbiology area to create a low oxygen tension required to the growth of anaerobic bacteria. Here, we hypothesized the use of AnaeroGen system to induce hypoxia in T24 human bladder carcinoma cells, in order to promote the overexpression of VEGF-A. T24 cells were cultured in six-well plates containing McCoy medium. Exposures of T24 cells to hypoxia for 1, 8, 24, and 48 h were performed using the Oxoid AnaeroGen system, while T24 cells under normoxia were used as control. The expression of VEGF-A and HIF-1 alpha was analyzed by real-time PCR. ELISA for HIF-1 alpha was carried out. The VEGF-A expression increased significantly by Oxoid AnaeroGen-induced hypoxia in a time-depending manner, reaching the peak in 48 h of hypoxia. Although HIF-1 alpha mRNA was not changed, HIF-1 alpha protein was increased in the presence of hypoxia, reaching a peak at 8 h. These results demonstrated that the Oxoid AnaeroGen system is a simple method to expose T24 cells to hypoxia and efficiently to upregulate VEGF expression in T24 cells. (AU)

• Processo FAPESP: 16/04105-0 - Potencial biomarcador e alvo terapêutico da indoleamina 2,3-dioxigenase (IDO) no câncer de bexiga
• Beneficiário: Humberto Dellê
• Modalidade de apoio: Auxílio à Pesquisa - Regular